The death of a study volunteer further complicates the path forward for Intellia’s on-hold rare disease treatment. Elsewhere, Gilead reported a setback and J&J netted a first-of-its-kind approval.

The brain drug developer plans to slash R&D expenses by about 60% in the wake of the FDA surprisingly rejecting its rare disease drug Vyglxia.

Back-to-back Presidential Symposium presentations of ENHERTU from DESTINY-Breast11 and DESTINY-Breast05 demonstrate its potential to become a foundational treatment in curative-intent settings of HER2 ...

Thinking about what to do with your Daiichi Sankyo Company shares? If you are watching your stocks closely or hunting for opportunities, you have probably noticed this name keeps popping up on analyst ...

Japan's Nikkei crosses 51,000 for first time on tech optimism Japan's Nikkei share average surged past the key 51,000 level for the first time on Wednesday, underpinned by investor optimism over ...

AstraZeneca and Daiichi Sankyo are teeing up a TROP2 showdown with Gilead Sciences in first-line triple-negative breast cancer. China's InnoCare Pharma agreed to out-license three autoimmune ...

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announced positive results from the DESTINY-Breast05 Phase III trial showed Enhertu demonstrated a highly statistically significant and clinically ...

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

AstraZeneca and Daiichi Sankyo have chalked up another positive trial for their HER2-directed antibody-drug conjugate Enhertu in early breast cancer, this time in the 'post-neoadjuvant' setting. The ...

AstraZeneca and Daiichi Sankyo pushed back the readout of their trial of Datroway in triple-negative breast cancer (TNBC) patients ineligible for frontline immunotherapies, but the result has been ...